Serametrix, Penn State Working to Personalize Immunotherapy for Pediatric Brain Cancer | GenomeWeb

Penn State Hershey Children's Hospital and Serametrix will collaborate on developing a serum-based assay that will measure autoantibodies to help doctors predict which patients are likely to respond to a brain cancer immunotherapy being developed by the hospital.

The partnership, announced this week, is part of the Pediatric Cancer Immunotherapy Program at Penn State Hershey Children's Hospital. Within this program, researchers are developing new treatments for children with relapsed tumors that aim to bolster their immune response against cancer cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.